DDMODEL00000069: Savic_transit_abs_glibenclamide_pk_original

  public model
Short description:
Transit compartment absorption model for glibenclamide metabolite 1 pharmacokinetics.
Original code
  • Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
  • Savic RM, Jonker DM, Kerbusch T, Karlsson MO
  • Journal of pharmacokinetics and pharmacodynamics, 10/2007, Volume 34, Issue 5, pages: 711-726
  • Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Uppsala 75234, Sweden. Rada.Savic@farmbio.uu.se
  • PURPOSE: To compare the performance of the standard lag time model (LAG model) with the performance of an analytical solution of the transit compartment model (TRANSIT model) in the evaluation of four pharmacokinetic studies with four different compounds. METHODS: The population pharmacokinetic analyses were performed using NONMEM on concentration-time data of glibenclamide, furosemide, amiloride, and moxonidine. In the TRANSIT model, the optimal number of transit compartments was estimated from the data. This was based on an analytical solution for the change in drug concentration arising from a series of transit compartments with the same first-order transfer rate between each compartment. Goodness-of-fit was assessed by the decrease in objective function value (OFV) and by inspection of diagnostic graphs. RESULTS: With the TRANSIT model, the OFV was significantly lower and the goodness-of-fit was markedly improved in the absorption phase compared with the LAG model for all drugs. The parameter estimates related to the absorption differed between the two models while the estimates of the pharmacokinetic disposition parameters were similar. CONCLUSION: Based on these results, the TRANSIT model is an attractive alternative for modeling drug absorption delay, especially when a LAG model poorly describes the drug absorption phase or is numerically unstable.
Gustaf Wellhagen
Context of model development: Mechanistic Understanding;
Model compliance with original publication: Yes;
Model implementation requiring submitter’s additional knowledge: Yes;
Modelling context description: Pharmacokinetics of glibenclamide metabolite 1 with transit compartment absorption;
Modelling task in scope: estimation;
Nature of research: Early clinical development (Phases I and II);
Therapeutic/disease area: Endocrinology;
Annotations are correct.
This model is not certified.
  • Model owner: Gustaf Wellhagen
  • Submitted: Oct 14, 2016 4:35:26 PM
  • Last Modified: Oct 14, 2016 4:35:26 PM
  • Version: 12 public model Download this version
    • Submitted on: Oct 14, 2016 4:35:26 PM
    • Submitted by: Gustaf Wellhagen
    • With comment: Edited model metadata online.